What are the key terms of Neil Warma’s ProMIS (PMN) share purchase warrants?

Neil Warma received 6,183 warrants to purchase ProMIS common shares at an exercise price of $14.40 per share. The warrants are exercisable from February 3, 2026 and expire on the earlier of February 3, 2031 or 60 days after topline PMN310 data is publicly reported.

ProMIS CEO buys 6,183 shares, gets warrants

ProMIS Neurosciences Inc. insider transaction: Chief Executive Officer and director Neil K. Warma acquired 6,183 common shares of ProMIS Neurosciences Inc. on February 3, 2026 at a price of $12.13 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. insider transaction: Chief Executive Officer and director Neil K. Warma acquired 6,183 common shares of ProMIS Neurosciences Inc. on February 3, 2026 at a price of $12.13 per share. He also received warrants to purchase 6,183 common shares at an exercise price of $14.40 per share.

The warrants become exercisable on February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from PMN310 single ascending dose cohorts.

Insider Trade Summary

Grant/Award: 12,366 shares

Grant/Award 2 txns

Insider Warma Neil K

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Warrants to purchase Common Shares	6,183	$0.00	$0.00
Grant/Award	Common Shares	6,183	$12.13	$75K

Holdings After Transaction: Warrants to purchase Common Shares — 6,183 contracts (Direct); Common Shares — 6,183 shares (Direct)

Footnotes (2)

F1. On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.
F2. The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ProMIS Neurosciences (PMN) report for Neil Warma?

Neil K. Warma acquired 6,183 ProMIS Neurosciences common shares and 6,183 related share purchase warrants on February 3, 2026. The shares were bought at $12.13 each, with the warrants allowing future purchases of the same number of shares at a set exercise price.

At what price did Neil Warma buy ProMIS Neurosciences (PMN) shares?

Neil Warma purchased 6,183 ProMIS Neurosciences common shares at $12.13 per share. The same transaction also included 6,183 common share purchase warrants, with a bundled purchase price of $12.13 per common share and warrant under a Securities Purchase Agreement with selected investors.

When do Neil Warma’s ProMIS Neurosciences (PMN) warrants expire?

The warrants held by Neil Warma expire on the earlier of February 3, 2031, or within 60 days after ProMIS publicly announces or files a Form 8-K with topline data from cohorts receiving single ascending doses of PMN310, whichever happens first.

What role does Neil Warma hold at ProMIS Neurosciences (PMN)?

Neil K. Warma is both Chief Executive Officer and a director of ProMIS Neurosciences Inc. His Form 4 filing reports his direct acquisition of 6,183 common shares and 6,183 common share purchase warrants under a Securities Purchase Agreement with selected investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/05/2026 - 08:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warma Neil K

(Last)

(First)

(Middle)

C/O PROMIS NEUROSCIENCES INC.

1920 YONGE STREET, SUITE 200

(Street)

TORONTO

M4S 3E2

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	02/03/2026		A⁽¹⁾		6,183	A	$12.13⁽¹⁾	6,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrants to purchase Common Shares	$14.4	02/03/2026		A⁽¹⁾		6,183		02/03/2026	02/03/2031⁽²⁾	Common Shares	6,183	⁽¹⁾	6,183	D

Explanation of Responses:

1. On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 6,183 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 6,183 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant.

2. The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310.

	/s/ Max A. Milbury, Attorney in Fact for Neil Warma	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR